Effects of Tirzepatide and Insulin Glargine on Glucolipid Metabolism and Brain Function in Patients With Type 2 Diabetes

Sponsor
Nanjing First Hospital, Nanjing Medical University
Study ID
NCT05553093
Phase
PHASE4
Status
Recruiting
Apply to this trial

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - 75 Years
Healthy Volunteers
Not accepted

Interventions

  • Tirzepatide — DRUG
    Tirzepatide ih qw
  • Insulin Glargine — DRUG
    6 IU ih qd

Study Details

The effects of Tirzepatide and Insulin Glargine on glucose and lipid metabolism and inflammation in patients with type 2 diabetes mellitus. Effects of Tirzepatide on the occurrence and development of cognitive impairment in diabetic patients and its associated pattern of changes in brain neural network characteristics.

Key Dates

Start date
Mar 15, 2022
Status verified
Sep 2022
Primary completion
Dec 31, 2023
Completion
Oct 31, 2027

Study Design

Enrollment
150 participants (estimated)
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT

Arms

  • Experimental: Tirzepatide
    Tirzepatide 5、10、15mg
  • Active Comparator: Insulin Glargine
    Insulin Glargine 6 international unit (IU)

Primary Outcome Measure

blood sugar changes [ Time Frame: 40 weeks ]

Central Contacts

Related Studies